Clinical trial Recruiting at 1 site Observational Ages 14 and up

National registry for chronic itch patients

Official title: Swiss Itch Registry (SWITCHR) - A Prospective Registry to Collect Data of Patients With Chronic Pruritus

Run by University Hospital, Basel, Switzerland · NCT06120907 · Data updated 2026-11-12

This study is creating a national registry for people in Switzerland with chronic itching to better understand their needs and improve treatment options.

Quick facts

Study typeObservational
Ages14 Years and up
SexAll
Enrollment100 (estimated)
SponsorUniversity Hospital, Basel, Switzerland
Academic / other
Locations1 site (Basel)
StatusRecruiting
StartedOctober 18, 2023
Main results expectedOctober 2033
Study endsOctober 2033
Registry record updatedDecember 13, 2024
Trial IDNCT06120907 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this registry are individuals aged 14 and older with a diagnosis of chronic pruritus and a minimum itch severity score.

Probably not a fit

Patients with conditions that prevent them from participating in the registry or those who refuse to complete necessary assessments may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to establish a national registry for patients suffering from chronic pruritus (itch) in Switzerland. Participants will undergo comprehensive assessments including patient-reported outcomes, physician evaluations, blood tests, and imaging techniques at specified intervals. The registry will facilitate a better understanding of patient needs, treatment outcomes, and safety issues related to chronic pruritus. Additionally, it will enable standardized comparisons of various pruritic conditions and enhance awareness among healthcare providers and authorities.

Why it matters

Potential benefit: If successful, this registry could significantly improve the management and treatment of chronic pruritus, leading to better patient outcomes.

How similar studies have gone: While this approach is novel in Switzerland, similar registries have shown success in other countries, indicating potential for impactful outcomes.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥ 14 years.
* Written informed consent of the patient.
* Diagnosis of CP irrespective of the International Forum for the Study of Itch (IFSI) group (I-III) and/or underlying cause (according to the judgment of the investigator).
* A Numerical Rating Scale (NRS) score of min. ≥ 4 within the last 7 days.
* Sufficient language skills (in the languages which the patient information and the consent form is available) to provide informed consent.

Exclusion Criteria:

* Any medical or psychological condition in the treating physician's opinion, which may prevent the patient in registry participation
* Lack of informed consent for registry participation.
* Refusal to complete Patient Reported Outcomes (PROs)

Where it's running

  • Department of Dermatology, University Hospital Basel
    Basel, Switzerland
    Recruiting

Study contacts

  • Principal investigator: Simon Mueller, PD Dr. med. — Department of Dermatology, University Hospital Basel
  • Study coordinator: Simon Mueller, PD Dr. med.
  • Email: simon.mueller@usb.ch
  • Phone: +41 61 328 69 64

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.